Voyager Therapeutics (NASDAQ:VYGR) Stock Price Crosses Below 50-Day Moving Average – Here’s What Happened

Voyager Therapeutics, Inc. (NASDAQ:VYGR) shares passed below its 50 day moving average during trading on Thursday . The stock has a 50 day moving average of $3.90 and traded as low as $3.55. Voyager Therapeutics shares last traded at $3.62, with a volume of 569,541 shares.

Wall Street Analyst Weigh In

A number of research analysts have recently weighed in on VYGR shares. Truist Financial raised shares of Voyager Therapeutics to a “strong-buy” rating in a research note on Wednesday, March 25th. HC Wainwright reissued a “buy” rating on shares of Voyager Therapeutics in a research note on Tuesday, May 26th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Voyager Therapeutics in a research report on Wednesday, April 15th. Finally, Wall Street Zen cut shares of Voyager Therapeutics from a “hold” rating to a “sell” rating in a research report on Saturday, May 9th. One analyst has rated the stock with a Strong Buy rating, two have issued a Buy rating and one has given a Sell rating to the company. According to data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $16.50.

Voyager Therapeutics Stock Performance

The firm has a market cap of $218.72 million, a price-to-earnings ratio of -1.84 and a beta of 1.25. The business’s 50 day moving average price is $3.90 and its 200-day moving average price is $3.97.

Voyager Therapeutics (NASDAQ:VYGR) last released its quarterly earnings data on Thursday, May 7th. The company reported ($0.47) earnings per share for the quarter, topping the consensus estimate of ($0.54) by $0.07. Voyager Therapeutics had a negative net margin of 319.61% and a negative return on equity of 55.97%. The firm had revenue of $1.19 million for the quarter, compared to analyst estimates of $8.79 million. On average, analysts forecast that Voyager Therapeutics, Inc. will post -1.61 earnings per share for the current fiscal year.

Insider Activity at Voyager Therapeutics

In other Voyager Therapeutics news, CEO Alfred Sandrock sold 11,511 shares of the firm’s stock in a transaction that occurred on Thursday, April 2nd. The shares were sold at an average price of $3.87, for a total value of $44,547.57. Following the sale, the chief executive officer owned 472,549 shares in the company, valued at approximately $1,828,764.63. This trade represents a 2.38% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders own 12.70% of the company’s stock.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently made changes to their positions in VYGR. Wexford Capital LP bought a new position in shares of Voyager Therapeutics in the third quarter valued at approximately $42,000. ProShare Advisors LLC acquired a new position in Voyager Therapeutics in the 4th quarter worth approximately $44,000. CIBC Asset Management Inc purchased a new stake in Voyager Therapeutics in the 4th quarter worth approximately $45,000. Coldstream Capital Management Inc. purchased a new stake in Voyager Therapeutics in the 3rd quarter worth approximately $55,000. Finally, EHP Funds Inc. purchased a new stake in Voyager Therapeutics in the 3rd quarter worth approximately $58,000. 48.03% of the stock is currently owned by institutional investors.

Voyager Therapeutics Company Profile

Voyager Therapeutics, Inc is a clinical-stage biotechnology company focused on the development of gene therapies for serious neurological diseases. The company’s core activities center on the design and delivery of engineered adeno-associated viral (AAV) vectors tailored to target cells in the brain and central nervous system. Through its proprietary CapsidMap and VectorMap platforms, Voyager aims to enhance vector potency, specificity and durability to address diseases with high unmet medical need.

The firm’s pipeline includes several AAV-based candidates in preclinical and early clinical development.